Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
– Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD
– Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo
– Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking